Skip to main content

Bristol Myers Squibb Growth Portfolio revenue

  • BMY · NYSE
  • Pharmaceuticals
  • S&P 500
$63.43+1.78%Close 13 Nov 2026 · Market value $128.9B

Growth Portfolio revenue at Bristol Myers Squibb came to $7.7B for the quarter to 30 Sep 2026, up 11.7% from a year earlier.

As Bristol Myers Squibb reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.

By quarter

$5.3BDec 2023$4.8BMar 2024$5.6BJun 2024$5.8BSep 2024$6.4BDec 2024$5.6BMar 2025$6.6BJun 2025$6.9BSep 2025$7.4BDec 2025$6.2BMar 2026$7.6BJun 2026$7.7BSep 2026
Bristol Myers Squibb Growth Portfolio revenue, every reported period
Period endingGrowth Portfolio revenueChange on a yearFiled
30 Sep 2026$7.7Bup 11.7%29 Oct 2026
30 Jun 2026$7.6Bup 14.6%30 Jul 2026
31 Mar 2026$6.2Bup 11.9%30 Apr 2026
31 Dec 2025$7.4Bup 16.2%11 Feb 2026
30 Sep 2025$6.9Bup 18.0%30 Oct 2025
30 Jun 2025$6.6Bup 17.9%31 Jul 2025
31 Mar 2025$5.6Bup 16.1%24 Apr 2025
31 Dec 2024$6.4Bup 21.0%12 Feb 2025
30 Sep 2024$5.8Bup 17.5%31 Oct 2024
30 Jun 2024$5.6Bup 18.0%26 Jul 2024
31 Mar 2024$4.8Bup 8.5%25 Apr 2024
31 Dec 2023$5.3B—13 Feb 2024
30 Sep 2023$4.9B—26 Oct 2023
30 Jun 2023$4.7B—27 Jul 2023
31 Mar 2023$4.4B—27 Apr 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Bristol Myers Squibb: International revenues · Gross product sales · Net product sales · Legacy Portfolio revenue · Eliquis revenue · Opdivo revenue · Orencia revenue · Yervoy revenue · Reblozyl revenue · Breyanzi revenue · Alliance and other revenues · Camzyos revenue · Opdualag revenue · Opdivo Qvantig revenue · Revlimid revenue · Zeposia revenue · Pomalyst/Imnovid revenue · Abecma revenue · Sotyktu revenue · Alliance revenues · Sprycel revenue · Abraxane revenue · Krazati revenue · Cobenfy revenue · financial statements

Every KPI and segment of BMY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.